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Cryptococcus gattii has emerged as a human and ani-
mal pathogen in the Pacific Northwest. First recognized on 
Vancouver Island, British Columbia, Canada, it now involves 
mainland British Columbia, and Washington and Oregon in 
the United States. In Canada, the incidence of disease has 
been one of the highest worldwide. In the United States, lack 
of cryptococcal species identification and case surveillance 
limit our knowledge of C. gattii epidemiology. Infections in 
the Pacific Northwest are caused by multiple genotypes, but 
the major strain is genetically novel and may have emerged 
recently in association with unique mating or environmen-
tal changes. C. gattii disease affects immunocompromised 
and immunocompetent persons, causing substantial illness 
and death. Successful management requires an aggressive 
medical and surgical approach and consideration of poten-
tially variable antifungal drug susceptibilities. We summarize 
the study results of a group of investigators and review cur-
rent knowledge with the goal of increasing awareness and 
highlighting areas where further knowledge is required.
C
ryptococcus gattii (formerly C. neoformans var. gattii) 
(1) is a basidiomycotic yeast acquired by inhalation. In 
a susceptible host, the disease (cryptococcosis), caused by 
C. gattii and the congeneric pathogen C. neoformans, usu-
ally results in pneumonia or dissemination to distant tissues, 
especially to the central nervous system. Some studies have 
shown that C. gattii appears to differ from other cryptococ-
cal pathogens in phenotypic characteristics, natural habitat, 
epidemiology, clinical disease manifestations and response 
to antifungal drugs. We briefly summarize these features 
before discussing the emergence of C. gattii in the Pacific 
Northwest region of Canada and the United States.
Based on the distribution of specific antigenic deter-
minants on the polysaccharide capsule, pathogenic cryp-
tococci have been divided into capsular serotypes B and 
C (both C. gattii), A (C. neoformans var. grubii), D (C. 
neoformans var. neoformans), and the hybrid diploid AD 
(1). Clinical and environmental C. gattii isolates obtained 
from most parts of the world belong to serotype B (2), 
the  serotype  also  responsible  for  cryptococcal  disease 
in the Pacific Northwest. The global distribution of C.   
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gattii serotype C appears relatively more geographically   
restricted (2–4).
C. gattii causes disease in healthy, immunocompetent 
persons  and  in  persons  with  immunosuppressive  condi-
tions, including those with HIV infection, organ transplant 
recipients,  and  patients  with  hematologic  malignancies 
(2,3,5,6). However, because clinical cryptococcal isolates 
are not routinely subtyped to the serotype or species level, 
the actual incidence of C. gattii infection in HIV-negative 
persons is not known. In a US population-based surveil-
lance study, 2 of 27 cryptococcal isolates obtained from 
HIV-negative persons were C. gattii (7). Although C. neo-
formans serotype A has been the most common cause of 
human disease worldwide since the HIV pandemic began, 
C. gattii may have previously caused proportionally more 
disease. For example, in Thailand in the pre-AIDS era, C. 
gattii comprised 66% of cryptococcal isolates, which de-
creased to ≈4% during the AIDS epidemic (8).
In general, cryptococcal disease can occur in 1 of 2 
ways: a primary disease progression in the context of im-
munosuppression, or reactivation of a subclinical, latent 
infection.  Progression  from  infection  or  colonization  to 
disease likely depends upon a complex interplay of factors 
associated with the host and the organism.
The natural history of C. gattii infection is not well un-
derstood, but some studies suggest subtle differences in dis-
ease caused by C. gattii and C. neoformans. C. gattii causes 
cryptococcomas in the lung and brain (often large, multifocal 
lesions) more commonly than C. neoformans, and C. gattii 
disease is more often associated with neurologic sequelae, 
frequently requiring aggressive neurosurgical management 
(9,10). Differences in clinical manifestations and outcome 
suggested by some studies may in part be explained by dif-
ferences in host immune status (9), although not all studies 
have demonstrated these differences (4).
Some reports have observed variable-to-decreased in 
vitro  antifungal  drug  susceptibilities  in  clinical  and  en-
vironmental C. gattii isolates (11,12); other studies have 
shown no differences (4). Clinical significance of in vitro 
susceptibility of cryptococcal isolates is unclear because 
testing methods are not standardized and MIC breakpoints 
have not been defined.
C. gattii is found typically in the tropics and subtrop-
ics (2). Accordingly, although detected in many regions, 
C. gattii has been found to be endemic to Australia and 
New Zealand, Papua New Guinea, South and Southeast 
Asia (Cambodia, Malaysia, Thailand, Vietnam, People’s 
Republic of China, Taiwan, Singapore, Nepal, and the In-
dian subcontinent), parts of Latin America (Argentina, Bra-
zil, Colombia, Uruguay, Paraguay, Peru, and Venezuela), 
southern California, Mexico, Hawaii, Central and South 
Africa,  and  certain  parts  of  Europe  (Austria,  Germany, 
France, Italy, Greece, and Spain) (2,13).
Our understanding of the epidemiology of cryptococ-
cosis is limited by our currently used diagnostic methods. 
Diagnosis  of  cryptococcosis  frequently  relies  on  direct 
microscopy,  culture  of  clinical  samples,  or  detection  of 
cryptococcal antigen in body fluids. However, the organ-
ism is not identified to species level in many clinical micro-
biology laboratories. One biochemical characteristic that 
distinguishes C. gattii from C. neoformans is its ability to 
produce blue coloration on  l-canavanine-glycine-bromo-
thymol blue (CGB) medium (14), although, occasionally, 
some isolates identified as C. gattii by molecular typing 
may be CGB negative (L. Hoang, unpub. data).
Molecular typing studies, which are essential in track-
ing C. gattii epidemiology, have used the techniques of 
PCR fingerprinting (15), restriction fragment length poly-
morphism  (RFLP)  analysis  (16),  intergenic  spacer  se-
quencing (17), amplified fragment length polymorphism 
analysis (18), and more recently, multilocus sequence typ-
ing (MLST) (19,20). Molecular typing has identified dis-
tinct haploid C. gattii lineages among clinical, veterinary, 
and environmental isolates, such as VGI, VGII, VGIII, and 
VGIV (19,21,22), which appear to have distinct biogeocli-
matic distribution zones. For example, most clinical isolates 
from Australia and eucalyptus-associated C. gattii isolates 
belong to molecular type VGI; VGII isolates have been 
found in domestic animals in Australia and in Aboriginal 
persons in the Northern Territory (2). On Vancouver Island 
and mainland British Columbia, most human, veterinary, 
and environmental C. gattii isolates belong to the genotype 
VGII, with its 2 molecular subtypes VGIIa (predominant 
genotype, ≈90% of VGII) and VGIIb (≈10%), representing 
2 independent clonal populations (20,22,23).
Emergence on Vancouver Island and 
in Mainland British Columbia
Isolated cases of C. gattii disease were identified in 
the animal population of British Columbia in 2000 (24). C. 
gattii disease was recognized as an epidemic on Vancouver 
Island and lower mainland British Columbia (23,25) and 
retrospectively found to have been affecting residents and 
travelers to the island, as well as the domestic and wild 
animal population, since 1999 (24).
In 2003, cryptococcal infection became a reportable 
disease in British Columbia, which strengthened surveil-
lance  efforts.  The  British  Columbia  Centre  for  Disease 
Control reported a cumulative incidence of 218 C. gattii 
cases in humans during 1999–2007, with an average of 
24.2 cases per year (26). The average annual incidence rate 
of C. gattii infection was 5.8 cases per million on mainland 
British Columbia and 25.1 cases per million on Vancou-
ver Island; this rate is higher than those reported in other 
C.  gattii–endemic  areas  of  the  world  (27).  During  this 
same period, 19 deaths from C. gattii disease were docu-
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mented, for a case-fatality rate of 8.7% (26). Of these 218 
cases, 55% were in men; the mean age at diagnosis was 
58.7 years. Possible risk factors included smoking, cancer, 
and HIV infection (26). Annual incidence, after reaching 
a plateau during 2000–2005, increased in 2006. Although 
most C. gattii cases have occurred among residents of Van-
couver Island the numbers of cases have steadily increased 
among residents of lower mainland British Columbia, likely 
caused by an active expansion of the epidemic zone since 
2004 from Vancouver Island to mainland British Colum-
bia and the northwestern United States (Washington and 
Oregon) (27). The exact mode of transmission of C. gattii 
from Vancouver Island to lower mainland British Colum-
bia is not known. However, studies of possible dispersal 
mechanisms have indicated an association of C. gattii cases 
with high-traffic locations, and evidence of anthropogenic 
dispersal through vehicle wheel wells, footwear, construc-
tion and forestry activity (leading to aerial dispersal), and 
water (23). A few domestic and international travelers to 
the disease-endemic zone on Vancouver Island have subse-
quently contracted cryptococcal disease caused by C. gattii 
VGIIa, the molecular subtype most commonly associated 
with the Vancouver Island emergence (28,29).
Emergence in the Northwestern United States
Use of MLST has documented that a C. gattii strain 
genetically similar to the Vancouver Island VGIIa strain 
caused disease in a patient in Seattle in 1971 (strain NIH444, 
also known as ATCC32609 and CBS6956). Another simi-
lar isolate was found in the environment in San Francisco, 
California, in 1990 (strain CBS7750) (20,22). These find-
ings indicate that this subtype of C. gattii was present in 
the environment (and may have been a cause of human 
disease) in this part of the United States for many years be-
fore recognition of the Vancouver Island emergence (20). 
In recent years, several cases of C. gattii disease have been 
recognized in Washington and Oregon.
In early 2006, the first US case of human infection by a 
C. gattii strain identical to the Vancouver Island VGIIa (as 
confirmed by MLST) was diagnosed in a resident of Orcas 
Island, Washington (30). From 2006 through July 2008, a 
total of 9 additional culture-confirmed cases were report-
ed in Washington in residents of Whatcom, Island, King, 
and San Juan counties (R. Baer, unpub. data). All C. gattii 
isolates from these patients in Washington belong to the 
VGIIa genotype, as indicated by RFLP (M. Morshed and 
L. Hoang, unpub. data) and MLST (31). Three of these 10 
patients had no travel history to Vancouver Island or other 
C. gattii disease–endemic areas. In addition, 1 Washington 
resident with sarcoidosis received a diagnosis of C. gattii 
disease in Oregon; the isolate from this patient belonged 
to a novel VGII genotype, VGIIc (31). Washington State 
now considers C. gattii infection notifiable as a rare disease 
of public health significance (www.doh.wa.gov/notify/nc/
cryptococcus.htm).
Cases of C. gattii disease have been identified in Or-
egon since 2004. During 2004–2005, two cases of culture-
confirmed C. gattii infection were recorded in the United 
States. These case-patients did not report exposure to Van-
couver  Island  or  other  C.  gattii–endemic  areas.  Isolates 
from  these  case-patients  (both  Oregon  residents)  were 
VGII, but they were genetically distinct from Vancouver 
Island VGII isolates and their relationship to the outbreak 
is unknown (27). The current count is 19 confirmed cases, 
as of May 2009 (S. West and K.A. Marr, unpub. data). As 
with case-patients seen in British Columbia and Washing-
ton, many of these patients had pulmonary manifestations. 
A review of the travel history of these patients suggests 
in-state acquisition, although with the currently considered 
incubation period of 6 weeks to 11 months for C. gattii dis-
ease (27,28), out-of-state acquisition cannot be ruled out. 
Additional cases are suspected because of increased reports 
of cryptococcal disease documented in otherwise healthy 
persons (K.A. Marr, unpub. data). However, the current 
epidemiologic understanding of the extent and spread of 
C. gattii disease in Washington and Oregon is incomplete 
because of the lack of culture isolation and strain identifica-
tion in clinical microbiology laboratories.
Veterinary Cases in the Pacific Northwest
Cryptococcal disease in animals is often characterized 
by  upper  respiratory  symptoms,  subcutaneous  nodules, 
pneumonia,  central  nervous  system  or  ocular  disorders, 
lymphadenopathy, or subcutaneous nodules (2,24,32). C. 
gattii infection was recognized in wild and domestic ani-
mals in British Columbia and Washington before human 
cases were detected, which reiterated the value of sentinel 
animal surveillance for emerging disease. To date, many 
species of animals, including dogs, cats, ferrets, porpoises, 
llamas, alpacas, birds, and a horse, have been confirmed to 
have C. gattii infections (23). During 2003–2005, C. gat-
tii VGIIa infections were detected on the lower mainland 
of British Columbia (in 1 ferret, 1 llama, and 6 cats) (27) 
and in northern Washington (3 cats and 4 porpoises) (27; 
E. Byrnes, pers. comm.). From August 2006 through July 
2008, C. gattii VGIIa was reported in 5 cats, 2 dogs, and 1 
parrot in Whatcom, Island, Yakima, and Snohomish coun-
ties of Washington (R. Wohrle, pers. comm.). In Oregon, 
VGIIa C. gattii infection was found in 2007 in 1 cat in Leb-
anon, 1 dog in Salem, and 2 alpacas in McMinnville and 
Sherwood (33).
Identified risk factors for animals include disturbance 
of soil or vegetation caused by hiking, digging, logging, 
and construction. These activities can potentially increase 
aerial dispersal of the infectious particles and contact with 
soil and tree cuttings (23). The distribution of isolates re-
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covered from human and animal sources and from the en-
vironment is shown in the Figure.
Ecologic Considerations
A possible association between C. gattii disease distri-
bution and eucalyptus trees was observed in the early 1990s 
in Australia (2), and sporadically elsewhere (34,35). How-
ever, this association is not uniform (11), which indicates 
additional environmental sources. In British Columbia, C. 
gattii has been isolated from surfaces of >10 noneucalyptus 
tree species, soil, air, freshwater, and seawater within the 
Coastal Douglas Fir and Coastal Western Hemlock biogeo-
climatic zones. These zones are characterized by warm, dry 
summers and mild, wet winters, a climate different from 
that traditionally associated with C. gattii (23). This find-
ing suggests either a change in the ecology and distribution 
of this organism, or identification of a previously unrecog-
nized niche (23,27).
From  the  beginning  of  the  C.  gattii  epidemic  on 
Vancouver Island and adjoining areas, all humans and 
animals with cryptococcal infection either lived within or 
traveled to the areas where C. gattii has been repeatedly 
and consistently isolated in subsequent studies (23,27). 
The Coastal Douglas Fir and Coastal Western Hemlock 
biogeoclimatic zones are located along the eastern edge 
of Vancouver Island, and extend into the southern Gulf 
Islands and lower mainland of British Columbia. Ecologic 
modeling of C. gattii in British Columbia has identified 
niche areas that are characterized by low-lying elevations 
(<770 m, average 100 m above sea level) and above freez-
ing daily winter average temperatures (S. Mak, unpub. 
data). Similar climates with comparable temperature and 
rainfall extend further south into Washington and Oregon. 
Additionally, the San Juan Islands, Puget Sound, and the 
Willamette  Valley  contain  plant  diversity  ecologically 
similar to that on Vancouver Island and in mainland Brit-
ish Columbia, lending support to the idea that C. gattii 
may  have  niche  areas  suitable  for  colonization  in  the 
broader Pacific Northwest (27).
Large-scale environmental sampling conducted from 
October 2001 through December 2005 in mainland British 
Columbia, the Gulf Islands, and Washington showed that 
60  (3%)  of  2,033  non-Vancouver  Island  environmental 
samples (air, water, soil, swabs of trees and other struc-
tures) were positive for C. gattii serotype B (58 VGIIa, 2 
VGI) (27). C. gattii was consistently isolated from some 
areas. However, it was not found in the environment in 
other areas, such as the San Juan Islands (36), which sug-
gests that environmental hot spots (zones of high concen-
tration) of C. gattii may be found within the same broad 
ecologic niches. Some areas may have transient coloniza-
tion, with initially positive sites yielding subsequent nega-
tive results (23).
Complicating the interpretation of epidemiologic data 
is the fact that the nature of the infectious propagule is cur-
rently unknown. Air sampling on Vancouver Island and in 
northern Washington has detected particles that are small 
enough to be either desiccated yeast cells or spores (23). 
Cryptococcus  species  are  haploid  yeasts  that  predomi-
nantly reproduce asexually (through mitosis and budding). 
However, they also possess a bipolar mating system, with 
mating types a or α. These mating types are capable of 
completing a sexual (meiotic) cycle that is either hetero-
sexual (between a and α) or unisexual (nonclassical union 
between α and α or a and a; also known as monokaryotic 
fruiting) (21). This cycle can produce spores that can be up 
to 100-fold more infectious than yeast cells and thus might 
represent the infectious source (37). In tree hollows, C. 
gattii populations can exist equally as only α-mating type 
isolates or as a- and α-mating type isolates; both undergo 
recombination (38). This observation, taken together with 
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Figure. Map of the Pacific Northwest, comprising parts of British 
Columbia, Canada, and the states of Washington and Oregon in 
the United States, showing human and veterinary Cryptococcus 
gattii  cases  (including  marine  mammals)  by  place  of  residence 
or detection, and locations of environmental isolation of C. gattii 
during  1999–2008  (strain  NIH444  [Seattle]  or  CBS7750  [San 
Francisco] not included). Data were collected from various state 
health departments and published reports referenced in the text. 
The map and icons have been used at a scale that shows gross 
geographic areas, effectively masking any personally identifiable 
patient locality information. Use of the map is courtesy of exclusive 
permission from Google Maps: 2008 Google, map data 2008 
NAVTEQ.C. gattii in Pacific Northwest, USA
the isolation of a diploid, homozygous α-mating type C. 
gattii strain from Vancouver Island, indicates that unique 
monokaryotic fruiting between α-mating type strains may 
be producing the infectious spores on Vancouver Island 
(20). Moreover, recent studies have shown that C. gattii is 
stimulated to complete its sexual cycle during an associa-
tion with plants (39).
The origin or introduction of C. gattii strains into the 
Pacific Northwest and factors encouraging their emergence 
as disease agents remain a mystery. Accurate determination 
of origin from any particular locale is difficult because of 
global dispersal and isolate recombination (19). Several hy-
pothesized disease movement models have been inconclu-
sive. As discussed above, C. gattii VGIIa strains may have 
existed for the past 35 years in the Pacific Northwest, and 
changing conditions of climate, land use, or host suscepti-
bility may have caused it to emerge at this time. An alterna-
tive hypothesis is that the VGIIa genotype is well adapted 
to the local biogeoclimatic conditions and enhanced with 
regards to virulence by virtue of the same-sex mating of 
the parents (20). Genetic studies putatively show that the 
dominant strain on Vancouver Island (VGIIa) originated in 
Australia, South America, or the Pacific Northwest. Con-
versely, the Vancouver Island minor genotype (VGIIb) is 
identical to fertile isolates from Australia and may well 
have originated on that continent (20,40).
Issues and Questions
We will now attempt to identify several major unmet 
needs  regarding  C.  gattii  disease  in  the  areas  of  public 
health, human and veterinary medicine, environmental sci-
ence, and microbiologic or basic research. Although en-
hancing a multidisciplinary awareness of C. gattii infection 
will encourage prompt, accurate diagnosis of patients with 
compatible clinical symptoms, many clinical microbiology 
laboratories in the United States are not currently equipped 
to identify the organism to the species level. Most labora-
tories use antigen testing or histopathologic analysis and 
report all isolates simply as C. neoformans; few laborato-
ries use biochemical tests that provide species level differ-
entiation. This practice should be reconsidered, especially 
in laboratories servicing disease-endemic regions.
Although formal C. gattii surveillance has been ongo-
ing in British Columbia since 2003, no routine surveillance 
program currently exists in the United States. Therefore, 
identified cases almost certainly represent an underestimate 
of the actual incidence of disease. Washington State has 
recently initiated a surveillance system for human crypto-
coccosis  cases  (www.doh.wa.gov/notify/nc/cryptococcus.
htm). However, to gather sufficient information about the 
true incidence of this disease and to perform necessary clin-
ical studies, a coordinated, systematic, regional approach to 
human and veterinary surveillance is needed.
Currently, the University of British Columbia and the 
British Columbia Centre for Disease Control hold a large 
collection of C. gattii isolates isolated from environmental, 
animal, and human sources. Additional central repositories 
of C. gattii strains and clinical databases would be useful 
for investigators in the field.
Animal models of C gattii disease are necessary for 
studying the pathogenicity of genetically diverse isolates 
and host immunity, as well as to answer more fundamen-
tal questions about the disease. Laboratory-based efforts 
should also focus on development of better diagnostic aids, 
such as a reliable system to isolate DNA from fixed tis-
sue. Development of species-specific serologic tests would 
enable seroprevalence studies for a better understanding 
of epidemiology and disease mechanisms. Studies of soil 
persistence and propagation of the organism and those that 
address the nature and factors controlling the infectious 
propagule would be informative (23).
Antifungal  drug  susceptibility  testing  represents  an 
area in need of improvement. Current susceptibility testing 
methods do not consider the unique in vitro growth condi-
tions of cryptococci, and interpretation of results is difficult 
in the absence of clinical breakpoints.
Some standardization in the performance of molecu-
lar techniques for genomic research is required. Different 
genotyping methods have their own particular advantages 
and disadvantages, and the method of choice varies con-
siderably among different laboratories. Random amplified 
polymorphic DNA analysis, RFLP, and amplified fragment 
length polymorphism analysis provide a lower resolution 
starting point, but may not be sufficient to rigorously estab-
lish strain identities, for which MLST approaches are nec-
essary. The appropriate method is obviously dependent on 
the desired level of discrimination of the strains. However, 
because the organism designations may vary with different 
methods,  common  nomenclature  should  be  standardized 
across molecular methods. Finally, further genome efforts 
should be encouraged; information comparing the genetic 
makeup of VG (I–IV) lineages might hold the key to under-
standing the differences in niches, virulence, mating, and 
the ability to cause an outbreak.
From a long-term public health perspective, it is impor-
tant to gain an understanding of how C. gattii disease was 
introduced and spread within the Pacific Northwest, includ-
ing the possible role of global climate change, deforestation 
and increased land use, as well as factors related to the biol-
ogy of the organism and changing host susceptibility. This 
knowledge, acquired through environmental and genomic 
research studies, would help identify high-risk groups or 
regions, and provide information on risk-reduction and im-
provement of diagnosis and treatment.
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Conclusions
C. gattii has become endemic to the Pacific Northwest. 
Efforts to understand the emergence on Vancouver Island 
and mainland British Columbia have generated valuable in-
formation. However, many questions remain unanswered. 
The Centers for Disease Control and Prevention (Atlanta, 
GA, USA) is currently working in conjunction with state 
public health departments to enable clinical (human and 
veterinary) surveillance. Additional organized national and 
international efforts are needed. As the first step, C. gat-
tii should be recognized as an emerging infection in the 
United States and declared a priority pathogen in the eyes 
of funding agencies.
Dr Datta is a postdoctoral fellow at Johns Hopkins Univer-
sity School of Medicine. His research interests include patho-
genic fungi and evaluation of host immune responses to these 
pathogens. 
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